federal - search results

If you're not happy with the results, please do another search

0 1258

Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts

Cannabis Science has completed its registration in the U.S. Government’s System for Award Management (SAM), and has applied for and received a Commercial and Government Entity (CAGE) Code from the Defense Logistics Agency’s CAGE Program Office at the U.S. Department of Defense. Cannabis Science is now listed with all U.S. companies eligible for Federal Government Contracts. “Achieving eligibility to access contracting opportunities with the U.S. Federal Government is a significant step for Cannabis Science,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, CEO, and Co-founder. “I believe we can leverage the unique experience and expertise of our company to win new business and grow Cannabis Science’s revenue base. We also plan to work closely with our strategic partners and collaborators to access Federal contracting and grant opportunities.”

Cannabis Science is registered in SAM with three North American Industry Classification System (NAICS) Codes:

§ 541711 – Research and Development In Biotechnology
§ 621511 – Medical Laboratories
§ 624230 – Emergency and Other Relief Services

SAM is the primary vendor database for the U.S. Federal Government. Having vendor information immediately available allows the U.S. Government to rapidly find the companies with the right capabilities to offer services for required government contracts, government initiatives, research & development projects, and particular supply needs, as well as for pandemic alert and other emergency requirements.

Cannabis Science intends to explore funding opportunities, individually and with its collaborators, with institutions such as the National Institutes of Health (NIH), institutes within NIH, such as the National Institute on Drug Abuse (NIDA), and others.

As part of its mandate to study drug abuse and addiction and other health effects of both legal and illegal drugs, NIDA funds a wide range of research on marijuana (cannabis); its main psychotropic ingredient, delta-9-tetrahydrocannabinol (THC); and chemicals related to THC (cannabinoids). Research suggests that THC and other cannabinoids may have potential in the treatment of pain, nausea, epilepsy, obesity, wasting disease, addiction, autoimmune disorders, and other conditions. NIDA has provided and continues to provide funding for research related to therapeutic uses of cannabinoids as it pertains to its mission, including studies on the use of THC and cannabidiol (CBD), another chemical constituent of marijuana, for the treatment of pain (as an alternative to opioid pain relievers), addiction, and other disorders. Research on therapeutic uses of marijuana or of specific chemicals in the marijuana plant for other diseases and conditions is supported by other components of NIH as is appropriate to their mission. For a complete listing of all projects funded by NIH examining the potential therapeutic benefits of cannabinoids, see the Therapeutic Cannabinoid Research category in the NIH Report database.

The vast majority of research proposals received and funded by NIH on therapeutic benefits of cannabinoids have examined individual cannabinoid chemicals or, in a few cases, marijuana leaves delivered through some means other than smoking. Research proposals submitted to any NIH Institute of Center (IC) to study therapeutic benefits of marijuana or one of its ingredients must meet the same accepted standards of scientific design as any other proposal and, on the basis of peer review, should meet public health significance and IC priorities to be competitive with other applications that qualify for funding. NIDA is a scientific, not a policy-making agency. The same is true for the NIH as a whole. NIDA’s role is to conduct and support scientific research on drugs and drug abuse and to advise the public and policy-makers, such as Congress, the White House Office of the National Drug Control Policy, and the U.S. Drug Enforcement Administration on the results of that research — with the goal of ensuring that the nation’s drug policies are informed by science. That said, NIDA does closely watch legislative changes both nationally and at the state level and supports research that studies how changing drug policies — for instance laws around recreational or therapeutic use of marijuana — affect rates of substance use and related public health issues.

0 4745

A group of lawmakers is yet again making another attempt to legalize marijuana on a federal level. Representative Thomas Garret sponsored the Ending Federal Marijuana Prohibition Act, which loosens the marijuana restriction and leaves it up to the state to make laws about recreational and medical marijuana.

States that have already legalized marijuana such as Colorado and California still violate federal law, making the ground work more confusing for establishing marijuana laws in the united states.

Eleven other sponsors introduced the bill back in February, however, they had very little effect on Capitol Hill. Garrett is in great hope that he will gain support even though President Trump has a firm stance to enhance federal laws on marijuana regulation. Garrett says that there are “redeeming medical uses for cannabis,” however, he does not always feel that way.

“The first time I heard the term ‘medicinal marijuana’ 25 or 30 years ago, I probably chuckled,” Garrett said on Wednesday.

He later started prosecuting marijuana users in Virginia.
Garrett stated: “My background on this issue is shaped by my own experiences as a criminal prosecutor, where in fact, I did enforce the laws of the Commonwealth of Virginia as they relate to marijuana, and some would say, did so quite vigorously.”

Gradually, he became sick of “creating criminals out of people who otherwise follow the law.” As a result, he started to suggest legalizing marijuana.

Garrett said: “If there’s anything I cannot tolerate as a citizen and as a prosecutor, it is the unequal application of justice.”
Representative Tulsi Gabbard has the same concerns regarding current marijuana laws.

“Every 42 seconds someone is arrested for the use or possession of marijuana, turning every-day Americans into criminals, tearing families apart,” Gabbard said, “The question before us is not whether you think marijuana use is good or bad, or how you feel about this issue, but whether we should be turning people into criminals.”

The president of Smart Approaches to Marijuana Kevin Sabet, who opposes legalizing marijuana, chided the “Cheech and Chong ideology.”

He said: “The marijuana industry is the next Big Tobacco of our time, and history will not look kindly upon those who enabled lobbyists and special interest groups to gain a foothold in putting profit ahead of public health and safety,”

    0 2010

    New legislation introduced by Senator Ron Wyden and Representative Earl Blumenauer, both Oregon Democrats, would take marijuana off the list of federally banned drugs, tax it at a rate similar to alcohol and tobacco, and end the threat of federal criminal penalties for businesses operating in states that allow the use of marijuana for recreational purposes. Democrats from marijuana legal states believe so many Americans have access to marijuana products that the federal government should start managing the industry.

    Marijuana businesses would gain access to the regulated banking system under the legislation. Many banks currently are reluctant to open accounts for marijuana businesses because of fears that the federal government could seize the money. Another measure, introduced by Wyden and Senators Michael Bennett (D-Colo.) and Rand Paul (R-Ky.), would allow marijuana businesses to claim federal deductions and tax credits, ending what the senators called a tax penalty on those businesses.

    Robert Capecchi, who oversees federal policy for the Marijuana Policy Project stated, “This is commonsense legislation that will eliminate the growing tension between federal and state marijuana laws. States are adopting laws designed to improve public safety by replacing the illegal marijuana market with a tightly regulated system of production and sales. The federal government should be working to facilitate that transition, not hinder it.”

    Anti-legalization supporters say the current balance between federal and state laws are unsustainable, and that marijuana use remains a danger to public health. Kevin Sabet, who runs Smart Approaches to Marijuana, a group that opposes legalization stated, “While we support federal laws against marijuana legalization, we don’t want to see folks locked up or given criminal records for smoking pot. While we don’t support an enforcement-centered war on drugs, we do support a targeted approach consistent with public health and social justice that stops the corporate interests driving Big Marijuana.”

    Oregon is one of eight states where voters have approved ballot measures to legalize marijuana for recreational use. Those new laws put states in conflict with federal law, which still considers marijuana an illegal drug. The vast majority of Americans live in states where marijuana is legal for medical purposes. Until now, the Department of Justice (DOJ) has taken an arms-length approach to legal marijuana states. A DOJ memo issued under the Obama administration deprioritized prosecution of marijuana-related activity, effectively allowing the industry to operate in states where it is legal.

    0 2266

    A new approach is under review to protect Colorado’s marijuana industry from a potential federal restriction. The state would forfeit millions of dollars in tax collections by doing so. A proposal in the Legislature would permit marijuana farmers and retailers to reclassify their recreational marijuana as medical marijuana if the change in law happens. This would be the most audacious move by an American marijuana state to avoid intervention in its cannabis market.

    The proposal would permit approximately 500 licensed recreational marijuana growers to reclassify their crop. The reclassification would cost the state more than $100 million a year because the tax on medical marijuana is substantially lower in comparison to recreational marijuana.

    The proposal says licensed farmers could become medical licensees “based on a business need due to a change in local, state or federal law, or enforcement policy.” The change wouldn’t take recreational marijuana off the books, but it wouldn’t entirely safeguard it either. What it could do is help farmers protect their inventory in case federal authorities start seizing recreational marijuana. The provision is getting a lot of attention in the marijuana industry following recent comments from members of President Donald Trump’s administration. White House spokesman Sean Spicer has said there’s a “big difference” between recreational and medical marijuana.

    Sponsors of the proposal call it a possible exit strategy for the new marijuana industry. It is hard to say how many businesses would be affected, or if medical marijuana would flood the market, because some businesses hold licenses to both sell and grow marijuana in Colorado. The state had about 827,000 marijuana plants growing in the retail system in June, the latest available data. More than half were for the recreational market.

    Senator Tim Neville, a suburban Denver Republican who sponsored the bill stated, “If there is a change in federal law, then I think all of our businesses want to stay in business somehow. They’ve made major investments.”

    If federal authorities start seizing recreational marijuana, Colorado’s recreational marijuana entrepreneurs “need to be able to convert that product into the medical side so they can sell it,” Neville stated. His proposal recently passed a committee in the Republican Senate four to one.
    However, it is unclear whether the bill could pass the full Colorado Senate or the Democratic House. Skeptics of the proposal doubt the classification change would do much more than cost Colorado tax money. Senator Lois Court, a Denver Democrat who voted against the bill stated, “It’s a big deal for our taxation system because this money has been coming in and has been set aside for this, that and the other.”

    0 3381

    A new proposal before legislators in Salem is arranged to protect people who purchase cannabis in Oregon. It’s considered emergency legislation, which means that if passed, it would immediately take effect. This proposal comes after comments from the federal government about pushing back on the six states that have legalized cannabis. Back on February 24, 2017, White House press secretary Sean Spicer said, “I do believe you will see greater enforcement of it.”

    When asked about medical cannabis, Spicer stated, “that is very different than recreational use, which is something the Department of Justice, I think, will be further looking into.” Currently, when you buy marijuana in Oregon, the business records your identification information to ensure you’re not purchasing more than the legal amount per day. The CEO of Cannabliss & Co. in Portland, Matt Price, says the need for minimal identification information is to ensure buyers are staying within the legal limit.

    Price stated, “If I have to purge the system and come up with some crazy way to track individuals it would be easy for people to abuse those powers.” Senate Bill 863 does two things. First, cannabis dispensaries or retailers wouldn’t be able to keep anyone’s information for more than four days. Second, it would make it illegal for the retailer or dispensary to give anyone’s information to anyone else. On the bottom of the bill’s summary it states the emergency act is “necessary for the immediate preservation of the public peace, health and safety.”

    Price stated, “There is a lot of fear in a new administration I think these guys are going to be a little more stringent but I don’t think they are going to be messing with any licensed legal state business.” Senator Floyd Prozanski is one of the key supporters of the bill he says the goal is to ensure voters got what they were expecting when they passed Measure 91. He says the hope would be to get the marijuana industry to be more like the alcohol industry, meaning marijuana stores check age but don’t keep consumers’ personal information.

    1 3258

    Federal law still holds the power even though voters have legalized recreational cannabis. Attorney General Jeff Sessions recently said, “I’m definitely not a fan of expanded use of marijuana. States, they can pass the laws they choose. I would just say it does remain a violation of federal law to distribute marijuana throughout any place in the United States, whether a state legalizes it or not.” Sessions’ remarks come after White House Press Secretary Sean Spicer told reporters, “I do believe you will see greater enforcement” of federal marijuana laws. Spicer continued, “When you see something like the opioid addiction crisis blossoming in so many states around this country, the last thing we should be doing is encouraging people.”

    If the Justice Department rekindles the mid-2000s war on state-legal cannabis, they should anticipate a bigger fight than any presidential administration has ever seen. A February Quinnipiac poll found Americans strongly oppose federal interference in states where cannabis is now legal. Colorado just finished its third year of collecting taxes and fees on recreational marijuana. According to tax data, the combined state revenue from Colorado’s marijuana industry has set a new record each year since implementation: $52.5 million in FY 2014-15, $85 million in 2015-16, and $127 million in 2016-17. While those figures include a 2.9% medical cannabis tax, the bulk of the money Colorado receives comes from a 10% sales and 15% excise tax on retail marijuana.

    Recreational cannabis has also created 18,000 jobs in Colorado alone. Denver’s industrial real estate market is booming. Pueblo County even has a marijuana-funded college scholarship program. Taylor West, deputy director of the National Cannabis Industry Association stated, “It is a very real industry sector in these states now, and there’s no evidence of buyer’s remorse on the part of voters.” The California voters who passed Proposition 64 probably aren’t feeling remorseful about that decision either. Once it begins issuing licenses, California is going to sell large amount of retail marijuana.

    0 1095

    Tauriga Sciences, Inc. Notified by Federal District Court New Jersey of April 17, 2017 Trial Status Conference

    A Trial Status Conference (“Status Conference”) has been scheduled for the date April 17, 2017; the Company expects that the date of the Trial (“Trial Date”) will be set during this Status Conference.

    The Company is seeking monetary damages at Trial in excess of $4,500,000 USD and the Company strongly believes in the merits of its case as well as the evidentiary record.

    Tauriga Sciences, Inc. ( OTC PINK : TAUG ) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company’s previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it’s seeking monetary damages in excess of $4,500,000 USD.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

    Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation: expectations, expects, anticipates, believes, hopes, beliefs, plans and objectives regarding the development, use and marketability of products as well as the attainment of certain corporate goals and milestones (i.e. SEC Periodic Filings, Filing of Proxies, etc.). Such forward-looking statements are based on present circumstances and on Tauriga’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Tauriga has little or no control. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by Tauriga with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

    0 2345

    The United States is in the grips of an opioid epidemic with no end in sight. President Donald Trump’s administration is set to introduce a federal restriction on the legalization of cannabis, the White House recently suggested. White House press secretary Sean Spicer said during his daily briefing session with reporters that the states enjoying tax revenue and job creation after legalizing marijuana will likely see “greater enforcement” of federal law banning cannabis in every shape and form.

    Spicer also contradicted known science and medical research by tacitly pinning the blame for the country’s heroin problem on cannabis. Not pharmaceutical industry-driven over prescription of painkillers, or a faulty reliance on medicine to solve pain. It’s cannabis that is driving Americans to overdose on painkillers and then, when that supply or their health insurance runs out, turn to heroin, Spicer stated. “I do believe you’ll see greater enforcement of it,” said Spicer, who added that the Justice Department will be “further looking into” marijuana enforcement. But on the other hand, Donald Trump is OK with medical marijuana.

    A federal restriction on legal marijuana is opposed by 71% of Americans, according to a Quinnipiac University poll figure. That figure would include about 40% of the minority of citizens who voted for Donald Trump. Trump’s latest approval ratings stand at a dismal 41%, with a majority of Americans finding the president “embarrassing.” Tom Angell, chair of the Marijuana Majority, a national advocacy organization stated, “If the administration is looking for ways to become less popular, cracking down on voter-approved marijuana laws would be a great way to do it. On the campaign trail, President Trump clearly and repeatedly pledged that he would leave decisions on cannabis policy to the states. With a clear and growing majority of the country now supporting legalization, reneging on his promises would be a political disaster and huge distraction from the rest of the president’s agenda.”

    1 2598

    Republican Congressman Dana Rohrabacher of California recently submitted a piece of legislation in the U.S. House of Representatives targeted at preventing the federal government from enforcing states that have legalized cannabis for recreational or medical use. The proposal, which is entitled the “Respect State Marijuana Laws Act of 2017,” would provide the marijuana community with immunity from federal punishment as long as they obey state law.

    Although the bill (H.R. 975) would not force Congress to end prohibition in a manner that would allow marijuana to be taxed and regulated nationwide similar to alcohol, it would amend the Controlled Substances Act in such a way that state legalization could carry on without the risk of federal interference. That means as long as cannabis consumers and their respective marketplaces adhere to the laws outlined by the state, this proposal would ensure Sessions and the DEA have no power to conduct raids or any other pesky shakedown tactics. However, for those states that still consider cannabis an illegal substance, no changes will happen.

    Robert Capecchi, director of federal policies for the Marijuana Policy Project, said in a statement, “This is commonsense legislation that is long overdue. It is time to end marijuana prohibition at the federal level and give states the authority to determine their own policies. Federal tax dollars should not be wasted on arresting and prosecuting people who are following their state and local laws.” Similar legislation has been introduced over the past couple of years, but those bills never even received a hearing. There is hope that with all of the controversy surrounding Sessions and the potential dismantling of the legal cannabis trade that Congress will get serious about listening to the issue of national marijuana reform in the 2017 session.

    0 1374

    According to a National Academies report released this month, more and more Americans are using cannabis both for recreational and medical purposes, however, scientists still don’t know very much about the drug’s effects on human physiology. Part of this knowledge gap owes to the fact that marijuana is classified as a Schedule I drug under the US Controlled Substances Act. In the eyes of the federal government, cannabis is a dangerous drug that “has no currently accepted medical use in treatment in the United States.” However, researchers in Canada are not far ahead of their United States counterparts, even though marijuana has since 2001 been functionally legal for medical use at the federal level there.

    Mark Ware, a McGill University pain management physician who has researched the safety and efficacy of cannabinoids for the past 18 years stated, “I wish I could say that [legalizing medical marijuana] had led to more research. I think there’s certainly a willingness to be able to document real world use of cannabis under a legal framework.” Ware added that while there are several public registries that track the legal use of marijuana among Canadians, experimental evidence on the effects of that use are lacking. He said, “The clinical trials, I think for most people that’s an expensive undertaking. There are still questions around who owns the intellectual property, who’s going to sponsor the trials, those remain barriers even in a legal framework as to the cost of that kind of research and the drug development piece of it.”

    Michael Bostwick, a psychiatrist at the Mayo Clinic in Rochester, Minnesota, has also published extensively on the therapeutic effects of marijuana. He agreed that although federal illegality is a primary obstacle to studying cannabis in the United States, there are other factors that make understanding the basic science behind the drug’s potential therapeutic effects a daunting prospect. “I’m not sure that the research can catch up with the social use, meaning this: that, at least within the current [US Food and Drug Administration] approaches to medication, which is how every other medication in our country is approved, there is no precedent and no model for, first, smoking a substance and, second, using a substance that is not pure but contains many, many different compounds in varying amounts.”

    The Food and Drug Administration (FDA) has only approved three drugs for human use that contain active ingredients present in or similar to those in botanical cannabis. These are Syndros and Marinol, which contain a synthetic version of delta-9-tetrahydrocannabinol (THC, the main psychoactive component of marijuana), and Cesamet, which contains a synthetic cannabinoid that has a chemical structure similar to THC.

    Ware suggested that instead of seeking to study smoked cannabis, researchers should shift to studying the therapeutic potential of extracts or derivatives of the plant or otherwise conduct research on alternative ingestion mechanisms, such as vaporization. He states, “There’s obviously a lot of non-scientific development in the recreational market in some of these areas, with edibles and vaping, and all that sort of thing, but I think if we can align some of that with therapeutic delivery systems, we could get away from the smoking. I think that’s a positive direction, more of those studies showing that it mimics the smoked route but it’s clearly less dangerous than smoking.”

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
    Ad Placements